NorthWest Biotherapeutics Inc (NWBO)

[Chiugray]

Thanks for the great examples of company valuations. It just makes me think about the potential, depth, and breadth of the DCVax platform:
- A first-in-class, cancer treatment technology (efficacy, basically no toxicity, quality of life, and potential for SOC and "cure")
- Broad patent protection
- Scalable manufacturing (Flaskworks, low cost)
- Validation (promising upcoming clinical trial data of actual patient's long term survival, and proving this efficacy against GBM, the emperor of all cancers)
- Personalized treatment (autologous)
- Address all solid cancers (DCVax-Direct)
- Continual optimization (modular/modulate, Linda Liau, UCLA combination treatments, e.g. DCVax + CI + CSF1R + poly ICLC)
- Systemic immune response (DCs use the entire immune system, adapts, and including immune memory to prevent cancer recurrence. Treats the entire body, addresses issue of cancer metastases. It is not a T-cell-only or a single target type, like many others are.)
- Broad potential for future applications (guessing but maybe as a prophylactic treatment for those with early stage cancers, or anything the immune system regulates)